Greenwich Lifesciences Outlines Plans to Expand FLAMINGO-01 Trial Sites, Reduce Costs, Pursue Additional Patent Filings, and Advance Partnering Strategy for GLSI-100
I'm PortAI, I can summarize articles.
Greenwich LifeSciences Inc. plans to expand its Phase III FLAMINGO-01 trial for GLSI-100 by adding 10 more sites in 2026 and considering expansion into the EU, UK, and Canada. The company aims to reduce costs by moving operations in-house and ending the use of a contract research organization. Additionally, it seeks to strengthen its patent portfolio and pursue partnerships. This strategy supports their ongoing financing and operational goals.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments